Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ANRO

Alto Neuroscience Inc

Dec 20 • 04:00PM ET

3.89

Dollar change +0.17
Percentage change 4.57	%

Healthcare • Biotechnology • USA • NYSE

Peers: LLY BIIB AXSM ACAD VRTX NBIX REGN BMY CYTK SRPT

| Held by: VTI IWM VXF IWO SCHA VTWO IWN IWC SCHB RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.13	Insider Own	18.60%	Shs Outstand	26.97M	Perf Week	1.57%
Market Cap	109.70M	Forward P/E	-	EPS next Y	-2.53	Insider Trans	0.29%	Shs Float	21.95M	Perf Month	-8.90%
Income	-57.45M	PEG	-	EPS next Q	-0.65	Inst Own	80.13%	Short Float	18.57%	Perf Quarter	-70.73%
Sales	0.00M	P/S	-	EPS this Y	73.42%	Inst Trans	37.05%	Short Ratio	5.14	Perf Half Y	-62.81%
Book/sh	6.12	P/B	0.64	EPS next Y	2.06%	ROA	-	Short Interest	4.08M	Perf Year	-
Cash/sh	6.44	P/C	0.60	EPS next 5Y	-	ROE	-	52W Range	3.56 - 24.00	Perf YTD	-81.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-32.35%	52W High	-83.79%	Beta	-
Dividend TTM	-	Quick Ratio	13.09	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	9.27%	ATR (14)	0.36
Dividend Ex-Date	-	Current Ratio	13.09	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	38.99	Volatility	8.19% 7.50%
Employees	63	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.62	Target Price	11.69
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-93.14%	Payout	-	Rel Volume	0.58	Prev Close	3.72
Sales Surprise	-	EPS Surprise	4.62%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	792.69K	Price	3.89
SMA20	-3.25%	SMA50	-32.22%	SMA200	-64.74%	Trades		Volume	461,654	Change	4.57%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-23-24	Downgrade	Wedbush	Outperform → Neutral	$29 → $4
Oct-23-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-03-24	Initiated	Wedbush	Outperform	$29
Feb-27-24	Initiated	William Blair	Outperform
Feb-27-24	Initiated	TD Cowen	Outperform
Feb-27-24	Initiated	Stifel	Buy	$32
Feb-27-24	Initiated	Robert W. Baird	Outperform	$32
Feb-27-24	Initiated	Jefferies	Buy	$33

Dec-11-24 08:03AM	Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (Business Wire)
Nov-28-24 08:06AM	Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline (PR Newswire)
Nov-12-24 04:10PM	Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -7.02%
Nov-04-24 08:00AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire) -6.78%
Oct-24-24 08:32AM	Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout (TipRanks) -5.28%
01:36PM	Loading…
Oct-23-24 01:36PM	Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform (Benzinga) -69.99%
08:03AM	Alto hits new low as depression drug flunks key test (BioPharma Dive)
07:32AM	Altos Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint (Clinical Trials Arena)
Oct-22-24 04:30PM	Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder (Business Wire)
Sep-05-24 09:27AM	15 Healthiest Countries in Asia (Insider Monkey) -5.07%
Sep-04-24 08:05AM	Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants (Business Wire)
Sep-03-24 08:05AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-24 04:05PM	Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +9.25% +6.01%
Jul-25-24 08:30AM	Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach (Business Wire)
Jul-16-24 07:30AM	Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder (Business Wire) +6.90%
01:58PM	Loading…
Jul-12-24 01:58PM	Hedge Fund and Insider Trading News: David Tepper, Bill Ackman, Josh Friedman, Whale Rock Capital Management, 352 Capital, Alto Neuroscience Inc (ANRO), Lions Gate Entertainment Corp. (LGF), and More (Insider Monkey)
Jun-20-24 08:05AM	Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia (Business Wire)
Jun-18-24 08:05AM	Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year 2024 Bay Area Award Winner (Business Wire)
Jun-10-24 09:00AM	Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On (InvestorPlace) +5.33%
May-29-24 08:05AM	Alto Neuroscience to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:05AM	Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer (Business Wire)
May-14-24 10:54PM	ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 (InvestorPlace)
04:03PM	Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
May-09-24 08:05AM	Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences (Business Wire) +5.19%
Apr-23-24 08:05AM	Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia (Business Wire)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
Apr-09-24 09:37AM	Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Apr-03-24 08:05AM	Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder (Business Wire)
Mar-21-24 04:05PM	Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights (Business Wire) +5.41%
Mar-11-24 08:05AM	Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors (Business Wire) +5.74%
08:00AM	Loading…
Mar-07-24 08:00AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire)
Feb-27-24 08:00AM	Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference (Business Wire) -6.21%
Feb-06-24 04:05PM	Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (Business Wire) -11.06%
Feb-01-24 08:57PM	Alto Neuroscience Announces Pricing of Upsized Initial Public Offering (Business Wire)

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Savitz Adam	CHIEF MEDICAL OFFICER	Jul 09 '24	Buy	12.60	12,069	152,085	36,920	Jul 11 04:15 PM
Savitz Adam	CHIEF MEDICAL OFFICER	Jul 10 '24	Buy	13.22	2,931	38,748	39,851	Jul 11 04:15 PM
Smith Nicholas Conrad	CHIEF FINANCIAL OFFICER	Mar 28 '24	Buy	16.36	6,150	100,628	26,866	Apr 01 04:15 PM
Alpha Wave Global, LP	10% Owner	Feb 06 '24	Buy	16.00	600,000	9,600,000	3,707,757	Feb 08 04:32 PM
Smith Nicholas Conrad	CHIEF FINANCIAL OFFICER	Feb 06 '24	Buy	16.00	1,563	25,008	1,563	Feb 07 04:40 PM
Savitz Adam	CHIEF MEDICAL OFFICER	Feb 06 '24	Buy	16.00	17,000	272,000	24,851	Feb 07 04:38 PM
Etkin Amit	PRESIDENT AND CEO	Feb 06 '24	Buy	16.00	3,125	50,000	1,205,465	Feb 07 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANRO

Alto Neuroscience Inc

Upgrade your FINVIZ experience